Find the Brexit cure for UK life sciences
Four months after the Brexit vote, the landscape is as uncertain for UK companies as on 24 June. The needs of life sciences must be understood and the sector given a bigger say in exit negotiations, says former health minister, Stephen Dorrell
Europe is currently a world leader in the fundamental science underpinning regenerative medicine and cell therapy, and in its therapeutic use and regulation. But how can Europe build on its leading position?
This new study shows ICT investments could cut healthcare costs for key ailments by more than 35%.
Science|Business and Sweden's Karolinska Institutet have conducted a survey of a wide range of stakeholders in personalised healthcare across four major EU-markets (Belgium, France, the Netherlands and the UK).
ETH Zurich: In a simple way to great complexity
ETH microbiologists have succeeded in showing that nature produces one of the most complex known bioactive natural products in a staggeringly simple way. The molecule originates from bacteria living in sea sponges. In future, it may be possible to produce the agent very easily using biotechnology, making it an interesting avenue for cancer research.
New £250m UK Dementia Research Institute to be led from UCL
UCL has been selected as the 'hub' of the new £250m UK Dementia Research Institute (UK DRI), to be led by Professor Bart De Strooper, current leader of the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and scientific director at VIB (Vlaams Instituut voor Biotechnologie) in Belgium.